– Antiretroviral, HIV protease inhibitor
– HIV infection, in combination with ritonavir (booster) and other antiretrovirals
Forms and strengths
– 200 mg capsule
– 300 mg atazanavir/100 mg ritonavir tablet
– Child 20 to < 25 kg: one 200 mg capsule once daily (+ 100 mg ritonavir once daily)
– Child ≥ 25 kg and adult: one 300 mg/100 mg tablet once daily
– The duration of treatment depends on the efficacy and tolerance of atazanavir and ritonavir.
Contra-indications, adverse effects, precautions
– Do not administer to patients with moderate and severe hepatic impairment or in combination with rifampicin.
– Administer with caution and monitor use in patients with haemophilia (increased bleeding) or in patients with mild hepatic impairment.
– May cause:
• jaundice, gastrointestinal disturbances, headache, insomnia, fatigue, peripheral neuropathy, asymptomatic hyperbilirubinaemia, cholelithiasis, urolithiasis, conduction disorders, hyperglycaemia, lipodystrophy;
• skin rash sometimes severe, hepatic disorders; in this event, stop treatment immediately.
– Administer with caution and monitor combination with drugs that prolong the QT interval (amiodarone, co-artemether, mefloquine, quinine, haloperidol, etc.).
– Monitor combination with omeprazole and antacids containing aluminium or magnesium hydroxide (effects of atazanavir decreased).
– Atazanavir in combination with ritonavir reduces the efficacy of oral contraceptives: use a non-hormonal contraception or injectable medroxyprogesterone or an oral contraceptive containing at least 30 micrograms of ethinylestradiol per tablet.
– Pregnancy: no contra-indication; monitor bilirubin levels and/or signs of jaundice in neonates.
– Take with meals together with ritonavir.
– Do not open the capsules.
– Also comes in 300 mg capsules, not in combination with ritonavir.
– Storage: below 25 °C -